Prospects for Novartis' nAMD eye treatment brolucizumab rose on news the novel anti VEGF treatment met primary and key secondary endpoints in two Phase III studies compared to Eylea, using less dosing.
Novartis AG's novel RTH258 (brolucizumab) has displayed an important differentiator and potential competitive advantage in twin Phase III studies for treating neovascular age-related macular degeneration (nAMD) by showing top-line non-inferiority to Eylea (aflibercept), with more half of the patients dosed every 12 weeks, versus every eight weeks for the comparator.
In the HARRIER trial, 52% of patients were maintained exclusively on every 12-week dosing, while that rose to 57% in...
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Ordspono, a bispecific antibody newly approved in the EU to treat follicular lymphoma and diffuse large B-cell lymphoma, joins Libtayo in Regeneron’s growing oncology portfolio.
Nemluvio is a first-in-class IL-31 inhibitor that the US FDA approved for prurigo nodularis.
CEO Bill Anderson would not be drawn on whether the drug, currently approved for chronic kidney disease associated with type 2 diabetes, will hit a previous forecast of €3bn peak sales, but expansion into heart failure may make that figure look conservative.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
